GMO Documentary Exposing Monsanto and Bayer


Looking to lose a few pounds while you get super healthy, increased flexibility, and increased well-being? We highly recommend this program. Click The Banner To Find Out More!


fbt-banner-728x901


This Monsanto Documentary or more broadly put GMO documentary about genetically modified organisms is meant to bring awareness to as many people as possible. GMO Documentary 2016.
Other Videos:
Edward Snowden Exposing NSA:

The Truth About Hillary Clinton:

GMO Documentary 2016
FB: https://goo.gl/o6F9ZR

Bayer makes B bid for Monsanto. Combination would create one of the world’s largest agrochemical businesses.

Follow us on:
*Facebook: https://www.facebook.com/HistoryRepeatsItselfYT
*Google+: http://google.com/+HistoryRepeatsItself
*Twitter: https://twitter.com/HistoryRPTSLF

http://historyrepeatsitselfyt.wordpress.com

Gmo Documentary about monsanto bayer and more gmo producers

German pharmaceutical and chemicals giant Bayer AG on Monday said it made an all-cash offer to acquire Monsanto Co. for billion, valuing the U.S. company at a substantial premium in a deal that would create the world’s largest agrochemicals company. German pharmaceutical and chemicals giant Bayer AG on Monday said it made an all-cash offer to acquire Monsanto Co. for billion, valuing the U.S. company at a substantial premium in a deal that would create the world’s largest agrochemicals company. The unsolicited proposal, which includes debt, would be the largest foreign takeover by a German company if accepted.

The move, which would eclipse a planned combination of Dow

Giving details for the first time, Bayer said on Monday it would offer 2 per share, a 37 percent premium to Monsanto’s stock price before rumors of a bid surfaced.

“We fully expect a positive answer of the Monsanto board of directors,” Baumann told reporters on a conference call, describing criticism from some investors as “an uneducated reaction in the media”, driven by an element of surprise.

Monsanto, which said last week it had a received an approach from Bayer but gave no details, has yet to comment on the offer. The U.S. company’s shares jumped 9.5 percent to 1.17 in pre-market trading. The gmo documentary offers you more knowledge about this.

Baumann is staking his claim as the global agrochemicals industry races to consolidate, partly in response to a drop in commodity prices that has hit farm incomes and also due to the growing convergence between seeds and pesticides markets.

ChemChina is buying Switzerland’s Syngenta for billion after Syngenta rejected a bid from Monsanto, while Dow and DuPont are forging a 0 billion business.

German chemicals group BASF has also been exploring a tie-up with Monsanto but is seen as unlikely to counter bid, sources close to the matter have said. BASF declined to comment on Monday.

Shares in Bayer, which had already fallen 14 percent since rumors of a bid emerged last week, dropped as much as 3.6 percent on Monday to a new 2-1/2 year low of 86.3 euros.

The offer values Monsanto at 15.8 times its earnings before interest, tax, depreciation and amortization for the year ended Feb. 29.

“UPPER LIMIT”

Markus Manns, a fund manager at Union Investment, Bayer’s 14th biggest investor, said a deal made sense but not at any price.

“The price that has now been disclosed is at the upper limit and it is just about economical. Should it rise further, which is to be assumed, the takeover will become increasingly unattractive,” he said.

Equinet analyst Marietta Miemietz, who has a ‘buy’ rating on Bayer stock, said: “While the leverage appears to be manageable from a (credit) ratings perspective, we believe that it would curtail Bayer’s strategic flexibility in the Healthcare space.”

The Food and Drug Administration is requiring that its most serious warning be placed on high-profile drugs for treating hepatitis C, saying they can cause a reactivation of hepatitis B and subsequently have led to death in some patients.

The direct-acting antiviral drugs – which include medicines under the brand names Sovaldi and Harvoni, as well as seven others – have high list prices that state governments, the Department of Veterans Affairs and prison systems have struggled to afford, with Sovaldi and Harvoni specifically costing tens of thousands of dollars for a full treatment.

More than 3 million people in the U.S. have hepatitis C, which is spread through blood and can necessitate a liver transplant.
#bayer
#bayermonsanto
#bayermakesoffertomonsanto
#62Bbidformonsanto
#monsanto
#gmo
#gmodocumentary

 

Add a Comment

Your email address will not be published. Required fields are marked *